For patients with locally advanced, large focal cervical cancer (IB2IIA2), the following treatment modalities are recommended in the guidelines for the treatment of cervical cancer published by the International Federation of Gynecology and Obstetrics (FIGO) in 2006: neoadjuvant chemotherapy followed by extensive hysterectomy and pelvic lymph node dissection and abdominal aortic lymph node sampling, and postoperative individualized therapy. The routes of administration of neoadjuvant chemotherapy for cervical cancer are divided into intravenous systemic chemotherapy and uterine artery infusion interventional chemotherapy. Interventional uterine artery perfusion neoadjuvant chemotherapy has many advantages and the following features: 1. The efficacy of the interventional artery perfusion operation itself is very mature, and the microcatheter can be inserted directly into the cervical branch of uterine artery, which further improves the chemotherapy effect. 2, interventional procedures are less risky, less traumatic (no incision, can get out of bed the next day), and have a short recovery time (2-3 days). 3.Surgical excision can be performed 2-3 weeks after single interventional neoadjuvant chemotherapy, avoiding the disadvantages of long cycle (1.5 months-2 months) and toxic side effects of intravenous neoadjuvant chemotherapy. 4.Improve staging, so that some patients get the opportunity to operate again. 5.Easy to separate the parametrial tissues during surgery and reduce the surgical damage. 6.It can reduce the risk of tumor cell shedding caused by intraoperative turning, extrusion or vascular blockage of the tumor, and inhibit lymph node metastasis and parametrial infiltration. 7.Patients with ineffective conservative treatment for bleeding can stop bleeding by embolization treatment at the same time. 8.Vaginal stenosis caused by radiotherapy can be avoided. 9.The cost is similar to intravenous neoadjuvant chemotherapy, and the hospital stay is short, avoiding the long waiting time caused by the long cycle of intravenous neoadjuvant chemotherapy and the progress of the disease due to the long waiting time. 10.High efficiency: the efficiency of single intervention (CR+PR) can reach more than 90%. Our department has long and close cooperation with gynecology department in the treatment of cervical cancer and has rich clinical experience. For patients with stage IB2IIA2 cervical cancer, we strongly recommend interventional uterine artery perfusion neoadjuvant chemotherapy before resection.